17th Jun 2015 09:16
LONDON (Alliance News) - Healthcare company Futura Medical PLC said Wednesday that it has continued to progress its product portfolio in line with its commercialisation plans in the year to date.
In a statement ahead of the company's annual general meeting, Futura said its clinical study of pain relief gels, diclofenac, ibuprofen and methyl salicylate began in March, and it expects headline results by the middle of next month. It is also at the advanced stage of preparations for its clinical study of MED2002 in erectile dysfunction.
It is working on a modified manufacturing process for its condom product CSD500, with the aim of extending its shelf life to meet industry requirements. It is encouraged by preliminary testing data it has received so far, and says it remains on track to file an extended shelf life product to regulators later this year.
Shares in Futura are trading down 1.2% at 40.01 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Futura Medical